YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first nine months of the fiscal year ended March 31, 2024, before the U.S. market opens on Friday, April 19, 2024.
馬里蘭州蓋瑟斯堡，2024 年 4 月 16 日 /PRNewswire/ — 致力於發現、開發、製造和交付用於傳染病和癌症的新一代疫苗和治療生物製劑的全球生物製藥公司 YS Biopharma 有限公司（NASDAQ：YS）（“YS Biopharma” 或 “公司”）今天宣佈，計劃發佈前九個月的財務業績截至2024年3月31日的財政年度，即2024年4月19日星期五美國市場開盤之前。
The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, April 19, 2024 to discuss the financial results. Listeners may access the call by dialing the following numbers:
公司管理層將於美國東部時間2024年4月19日星期五上午8點舉行業績電話會議，討論財務業績。聽衆可以通過撥打以下號碼來接聽電話：
|
United States Toll Free: |
1-888-346-8982 |
|
International: |
1-412-902-4272 |
|
Mainland China Toll Free: |
4001-201203 |
|
Canada Toll Free: |
1-855-669-9657 |
|
Hong Kong: |
852-301-84992 |
|
美國免費電話： |
1-888-346-8982 |
|
國際： |
1-412-902-4272 |
|
中國大陸免費電話： |
4001-201203 |
|
加拿大免費電話： |
1-855-669-9657 |
|
香港： |
852-301-84992 |
Upon dialing-in, participants should ask to be joined into the YS Biopharma Co., Ltd. call.
撥入後，參與者應要求加入YS Biopharma有限公司的電話會議。
The replay will be accessible through April 26, 2024 by dialing the following numbers:
撥打以下號碼可在 2024 年 4 月 26 日之前觀看重播：
|
United States Toll Free: |
1-877-344-7529 |
|
International: |
1-412-317-0088 |
|
Canada Toll Free: |
1-855-669-9658 |
|
Access Code: |
2468327 |
|
美國免費電話： |
1-877-344-7529 |
|
國際： |
1-412-317-0088 |
|
加拿大免費電話： |
1-855-669-9658 |
|
訪問碼： |
2468327 |
A live and archived webcast of the conference call will also be available at the Company's investor relations website at
電話會議的網絡直播和存檔網絡直播也將在公司的投資者關係網站上公佈
About YS Biopharma
關於 YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit .
YS Biopharma是一家全球生物製藥公司，致力於發現、開發、製造和商業化用於傳染病和癌症的新一代疫苗和治療性生物製劑。它開發了專有的PIKA免疫調節技術平台和一系列預防和治療生物製劑，有可能改進狂犬病、冠狀病毒、乙型肝炎、流感和帶狀皰疹疫苗。YS Biopharma在中國、美國、新加坡和菲律賓開展業務，由管理團隊領導，該團隊結合了豐富的本地專業知識和生物製藥行業的全球經驗。欲了解更多信息，請訪問。
Investor Relations Contact
投資者關係聯繫人
Alyssa Li
Director of Investor Relations
Email: [email protected]
Alyssa Li
投資者關係董事
電子郵件：[電子郵件保護]
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: [email protected]
楊羅賓
ICR, LLC 合夥人
電話：+1 (212) 537-4035
電子郵件：[電子郵件保護]
SOURCE YS Biopharma Co., Ltd.
來源 YS Biopharma Co., Ltd.
譯文內容由第三人軟體翻譯。